Key result
Nivolumab therapy in a 69-year-old man with metastatic lung adenocarcinoma was associated with life-threatening immune-mediated pericarditis and pericardial tamponade, which resolved with treatment.
Case Report (n=1)
Immune checkpoint inhibitors like nivolumab can cause rare but life-threatening cardiotoxicity such as immune-mediated pericarditis with tamponade, which requires prompt recognition and management.
Alerts clinicians to monitor for tamponade on nivolumab; leaves open true incidence and risk factors.
A 69-year-old man with metastatic lung adenocarcinoma presented with pericarditis and pericardial tamponade during nivolumab treatment, despite near-complete response on images performed during response evaluation. Further investigation found no evidence of pericardial or pleural cancer involvement, and pathologic evaluation showed immune-related adverse effect. Surgical and steroid treatments were used, with excellent results, and no disease progression on follow-up despite drug discontinuation because of toxicity. Although life-threatening immune-related adverse effects are not frequent when using checkpoint inhibitors, and cardiotoxicity is very rare, different clinical manifestations may occur, and some of them can be fatal in case of inadequate management. It may be challenging to make an etiological diagnosis; however, favorable outcomes can be achieved when prompt directed treatment is promoted.
No takes yet. Share an insight, caveat, or question.
Almeida et al. (2018) conducted a case report in Metastatic lung adenocarcinoma (n=1). Nivolumab was evaluated on Immune-mediated pericarditis with pericardial tamponade. Nivolumab therapy in a 69-year-old man with metastatic lung adenocarcinoma was associated with life-threatening immune-mediated pericarditis and pericardial tamponade, which resolved with treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: